So that — those are three big flagship products that’s very rare to have them all within kind of an 18-month period. That’s a super cycle. But beyond that, obviously, Insignia product is going to continue to launch. We have the CD Next product, which allows for depth perception as you are drilling. We have Signature 2 in the — which is launched just this year, which is going to have a full effect next year in neurocranial, which is for neuro power drills. And I could list another whole bunch of foot and ankle products. We have got products in the shoulder space. So it — there’s a full, full list of products. But those big ones I mentioned are that’s what I call it a super cycle is, you normally have one of those every two years or three years, not all in a short compressed timeframe.
You have got the ProCuity bed that’s continuing to get rave reviews and that’s kind of still in the early phases of its launch. So, as healthy as I have had in my time here at Stryker in terms of new product cadence. On China?
Jason Beach: Yeah. Vic, as it relates to China, as you all know, right, China, as it relates to total Stryker less than 2% of our sales. So even as you consider some of the lockdowns and things in 2022, immaterial to our results in terms of Q4. Then as you think about 2023, early days as it relates to Neurovascular VBP. We are certainly keeping an eye on that and as we think about Q1 and the full year of 2023, when we get to the next earnings call, if there’s anything material to disclose, we will certainly do it at that time.
Operator: The next question comes from Matt Miksic with Barclays. You may proceed.
Matt Miksic: Yeah. I just wanted to maybe get a sense and I know we could spend a lot of time talking about the many things that are going well and could go really well this year. But just a follow-up on Spine, the investment in the robot is significant, the portability of that hardware and upgrading the app, as you described, Kevin, is great. Between now and then, whether it’s Q Guidance or whether it’s implant launches or system launches or investments that you are making, can you talk about maybe anything that you would see as kind of gradually driving up momentum in that business as you head into — as you get into that introduction of the robot next year?
Kevin Lobo: Yeah. Yeah. Sure, Matt. So, certainly, we can’t just wait only for Mako and I’d tell you that Q Guidance has actually exceeded our expectations. Customer feedback has been excellent on that and the sales of those systems have been terrific. We also have a bunch of distribution deals that we have entered into for expandables, for different products, so two or three of those. We have the Monterey new product as well with Tritanium, which is pretty exciting. So it’s — we do have a, what we will call it a cadence of new products planned that will be either developed by Stryker or through distribution to help fill product gaps. I am pretty excited we have our sports medicine leader, Andy Hamel, who’s the Head of R&D, has moved over to Spine.
